Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
Φόρτωση...
Ημερομηνία
Συγγραφείς
Nikas, S. N.
Voulgari, P. V.
Alamanos, Y.
Papadopoulos, C. G.
Venetsanopoulou, A. I.
Georgiadis, A. N.
Drosos, A. A.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Ann Rheum Dis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. METHODS: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor alpha inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. RESULTS: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months' adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study-two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study-one because of lack of efficacy and two owing to side effects. CONCLUSION: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.
Περιγραφή
Λέξεις-κλειδιά
Aged, Antibodies, Monoclonal/*administration & dosage/adverse effects/therapeutic use, Antibodies, Monoclonal, Humanized, Antirheumatic Agents/*administration & dosage/adverse effects/therapeutic use, Arthritis, Rheumatoid/*drug therapy/immunology/physiopathology, Blood Sedimentation, C-Reactive Protein/analysis, Drug Administration Schedule, Female, Health Status Indicators, Humans, Joints/physiopathology, Male, Middle Aged, Platelet Count, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15975964
http://ard.bmj.com/content/65/2/257
http://ard.bmj.com/content/65/2/257
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής